- In August 2024, Lupin Ltd. launched Doxorubicin Hydrochloride Liposome Injection in 20 mg/10 mL and 50 mg/25 mL formulations, expanding its oncology portfolio and providing a critical cancer treatment option with improved patient compliance through liposomal delivery
- In February 2024, The U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma, marking a significant advancement in liposomal drug applications for cancer therapy
- In May 2023, Gencor and Pharmacy Biotech launched PlexoZome technology, an advanced targeted delivery liposomal system for liquid formulations, offering customizable and stable liposomal ingredients to enhance drug delivery efficiency
- In June 2022, Endo International's subsidiary, Endo Ventures Limited, entered into an agreement with Taiwan Liposome Company to commercialize TLC599, an investigational injectable compound in phase 3 development for osteoarthritis knee pain, highlighting the expanding scope of liposomal formulations in pain management
In January 2022, Pfizer and Acuitas Therapeutics established a Development and Option agreement, granting Pfizer a non-exclusive option to license Acuitas' lipid nanoparticle (LNP) technology for potential use in up to 10 targets, reflecting the growing interest in lipid-based delivery systems for vaccines and therapeutics
